The stock of Protagonist Therapeutics Inc (PTGX) has gone down by -6.46% for the week, with a 5.77% rise in the past month and a 3.83% rise in the past quarter. The volatility ratio for the week is 4.68%, and the volatility levels for the past 30 days are 4.04% for PTGX. The simple moving average for the past 20 days is -7.52% for PTGX’s stock, with a 12.51% simple moving average for the past 200 days.
Is It Worth Investing in Protagonist Therapeutics Inc (NASDAQ: PTGX) Right Now?
The price-to-earnings ratio for Protagonist Therapeutics Inc (NASDAQ: PTGX) is 66.00x, which is above its average ratio. Moreover, the 36-month beta value for PTGX is 2.26. Analysts have varying opinions on the stock, with 6 analysts rating it as a “buy,” 4 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for PTGX is 58.35M and currently, short sellers hold a 10.13% of that float. On July 02, 2025, PTGX’s average trading volume was 1.04M shares.
PTGX) stock’s latest price update
The stock of Protagonist Therapeutics Inc (NASDAQ: PTGX) has decreased by -9.16 when compared to last closing price of 55.27.Despite this, the company has seen a loss of -6.46% in its stock price over the last five trading days. accessnewswire.com reported 2025-06-26 that Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS Newswire / June 26, 2025 / Protagonist Therapeutics, Inc. (“Protagonist” or the “Company”) today announced that the company will host a conference call and webcast to announce its oral obesity development candidate and to share in vitro and pre-clinical proof-of-concept study results. Conference Call and Webcast Details The dial-in numbers for Protagonist’s investor update on Monday, June 30th at 4:30 pm ET are: US-based Investors: 1-877-407-0752International Investors: 1-201-389-0912Conference Call ID: 13754335 The webcast link for the event can be found here: https://viavid.webcasts.com/starthere.jsp?ei=1724439&tp_key=584cdd1e86 A replay of the presentation will be available on the Company’s Investor Relations Events and Presentations webpage following the event.
Analysts’ Opinion of PTGX
Many brokerage firms have already submitted their reports for PTGX stocks, with Citigroup repeating the rating for PTGX by listing it as a “Buy.” The predicted price for PTGX in the upcoming period, according to Citigroup is $72 based on the research report published on June 17, 2025 of the current year 2025.
Goldman, on the other hand, stated in their research note that they expect to see PTGX reach a price target of $47. The rating they have provided for PTGX stocks is “Neutral” according to the report published on December 06th, 2024.
BMO Capital Markets gave a rating of “Outperform” to PTGX, setting the target price at $62 in the report published on December 06th of the previous year.
PTGX Trading at 2.69% from the 50-Day Moving Average
After a stumble in the market that brought PTGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -17.15% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PTGX starting from MOLINA ARTURO MD, who sale 10,000 shares at the price of $57.03 back on Jun 10 ’25. After this action, MOLINA ARTURO MD now owns 83,892 shares of Protagonist Therapeutics Inc, valued at $570,300 using the latest closing price.
MOLINA ARTURO MD, the Chief Medical Officer of Protagonist Therapeutics Inc, sale 10,000 shares at $55.51 during a trade that took place back on Jun 09 ’25, which means that MOLINA ARTURO MD is holding 83,892 shares at $555,100 based on the most recent closing price.
Stock Fundamentals for PTGX
Current profitability levels for the company are sitting at:
- 0.13 for the present operating margin
- 0.99 for the gross margin
The net margin for Protagonist Therapeutics Inc stands at 0.27. The total capital return value is set at 0.04. Equity return is now at value 8.99, with 8.19 for asset returns.
Based on Protagonist Therapeutics Inc (PTGX), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at 29.66.
Currently, EBITDA for the company is 252.84 million with net debt to EBITDA at -4.48. When we switch over and look at the enterprise to sales, we see a ratio of 14.36. The receivables turnover for the company is 7.67for trailing twelve months and the total asset turnover is 0.28. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.26.
Conclusion
To wrap up, the performance of Protagonist Therapeutics Inc (PTGX) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
